
Claims

1. A compound of Formula (I)







(I)

or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein:

each R^1 is independently H or F;

R^2 is H, $(C_1\text{-}C_4)$alkyl, hydroxy$(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy$(C_1\text{-}C_4)$alkyl or $(C_1\text{-}C_4)$alkyl substituted by one, two or three F;

each R^3 is independently H, F, $(C_3\text{-}C_5)$cycloalkyl, $(C_1\text{-}C_4)$alkyl or $(C_1\text{-}C_4)$alkyl substituted by one, two or three F; or both R^3 taken together with the carbon atom to which they are attached form $(C_3\text{-}C_5)$cycloalkyl;

R^4 is selected from  or , wherein each  or  is optionally substituted with one or two substituents independently selected from oxo, $(C_1\text{-}C_4)$alkyl, hydroxy$(C_1\text{-}C_4)$alkyl and $(C_1\text{-}C_4)$alkyl substituted by one, two or three F; and

R^5 and R^6 are each independently H; halogen; OH; CN; $(C_1\text{-}C_6)$alkyl; hydroxy$(C_1\text{-}C_6)$alkyl; $(C_1\text{-}C_4)$alkoxy$(C_1\text{-}C_6)$alkyl; $(C_1\text{-}C_6)$alkyl substituted by one, two or three F; $(C_1\text{-}C_6)$alkoxy; or $(C_1\text{-}C_6)$alkoxy substituted by $(C_1\text{-}C_4)$alkoxy.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein each R^1 is H.

3. The compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^2 is H or $(C_1\text{-}C_4)$alkyl.


4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein each R^3 is independently H, F or (C_1-C_4)alkyl.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein each R^3 is independently H, F or methyl.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein one R^3 is H and the other R^3 is methyl.


8. The compound according to claim 7 of Formula (Ia)



(Ia)


or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^4 is




optionally substituted by one or two substituents independently selected from oxo, (C_1-C_4)alkyl and hydroxy(C_1-C_4)alkyl.

10. The compound according to claim 9, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^4 is



11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^4 is



12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are each independently H; halogen; OH; CN; $(C_1$-$C_3)$alkyl; hydroxy$(C_1$-$C_3)$alkyl; $(C_1$-$C_3)$alkoxy$(C_1$-$C_3)$alkyl; $(C_1$-$C_3)$alkyl substituted by one, two or three F; $(C_1$-$C_3)$alkoxy; or $(C_1$-$C_3)$alkoxy substituted by $(C_1$-$C_3)$alkoxy.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^5 is H, halogen, CN, $(C_1$-$C_3)$alkyl, $(C_1$-$C_3)$alkoxy or $(C_1$-$C_3)$alkoxy substituted by $(C_1$-$C_3)$alkoxy.

14. The compound according to claim 12 or claim 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein R^6 is H; halogen; OH; CN; $(C_1$-$C_3)$alkyl; hydroxy$(C_1$-$C_3)$alkyl; $(C_1$-$C_3)$alkoxy$(C_1$-$C_3)$alkyl; $(C_1$-$C_3)$alkyl substituted by one, two or three F; or $(C_1$-$C_3)$alkoxy.

15. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, selected from the group consisting of:

(S)-*N*-methyl-*N*-(6-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide;

(R)-*N*-methyl-*N*-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-(tetrahydro-2*H*-pyran-4-yl)propanamide;

(R)-*N*-(7-fluoro-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-(tetrahydro-2*H*-pyran-4-yl)propanamide;

(S)-*N*-(7-fluoro-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide;

(S)-*N*-ethyl-*N*-(7-fluoro-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide;

(S)-*N*-(6,7-difluoro-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide;

(S)-*N*-(6.7-difluoro-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-*N*-ethyl-2-morpholinopropanamide;

(S)-*N*-(7-fluoro-6-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-*N*-methyl-2-morpholinopropanamide; and

(S)-*N*-methyl-*N*-(7-methyl-2-((4a*S*,5a*R*)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[*f*]indazol-3-yl)-1*H*-benzo[*d*]imidazol-5-yl)-2-morpholinopropanamide.


16. The compound according to claim 15 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof.

17. The compound according to claim 15 which is (R)-*N*-methyl-*N*-(2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-(tetrahydro-2*H*-pyran-4-yl)propanamide, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof.

18. The compound according to claim 16 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide, or a hydrate thereof.

19. The compound according to claim 18 which is (S)-*N*-methyl-*N*-(6-methyl-2-((4aS,5aR)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazol-3-yl)-1*H*-benzo[d]imidazol-5-yl)-2-morpholinopropanamide, dihydrate.

20. The compound according to claim 16 which is



.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

22. The pharmaceutical composition according to claim 21 adapted for topical administration.

23. The pharmaceutical composition according to claim 21 or claim 22, further comprising one or more additional therapeutic agents.

24. The compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, for use as a medicament.

25. The compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, for use in the treatment of a disorder for which an ITK inhibitor is indicated.

26. The compound for use according to claim 25 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein the disorder for which the ITK inhibitor is indicated is a dermatological disorder.

27. The compound for use according to claim 26 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein the dermatological disorder is dermatitis.

28. The compound for use according to claim 27 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, wherein the dermatitis is atopic dermatitis.

29. Use of a compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder for which an ITK inhibitor is indicated.

30. Use of a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or said pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder in a human or animal for which an ITK inhibitor is indicated, wherein a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof is to be administered to said human or animal.